Autopsy report · NCT00460551
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
Cause of deathOther
“Due to considerations regarding the appropriate therapeutic regimen for these patients.”
Life of this trial
- Ran for about 1 year 6 months before it stopped.
- 13 participants enrolled.
- Results were posted on the registry 3 years 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Genmab
- Sponsor type
- Industry
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Zalutumumab; Induction chemotherapy; Radiotherapy
- Participants
- 13
- Sites
- 8
- Countries
- Belgium, France, Netherlands, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.